Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

January 12, 2026 09:00 ET Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma (“SCAC”), a setting with no U.S. Food and Drug Administration (“FDA”)-approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients. Updated GOBLET Cohort 4 Third-Line Anal Cancer Data As of the current data cut, four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate (“ORR”) of approximately 29%. These responses included two complete responses and two partial responses. The median duration of response (“DOR”) is approximately 17 months (67 weeks), indicating both depth and durability of clinical benefit in a heavily pretreated population. Patients enrolled in this cohort had progressed following multiple prior systemic therapies and represent a highly refractory disease population. In historical third-line SCAC studies, objective response rates are typically approximately 10% or less, with limited durability. 1, 2 There are currently no FDA-approved therapies for patients with third-line anal cancer. The observed response rate and emerging durability in GOBLET Cohort 4 compare favorably with historical outcomes and highlight the potential clinical relevance of pelareorep plus atezolizumab in this setting of significant unmet medical need. “As we continue to analyze the Goblet data, we are finding important trends that are helping to shape our clinical development strategy,” said Jared Kelly, Chief Executive Officer of Oncolytics. “When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies. We already had good data here, but looking closer, it becomes clearer that we can make an immediate impact on patients’ lives who have no options.” In the second-line setting, pelareorep and atezolizumab achieved a 30% ORR, more than doubling the 13.8% ORR that was approved by the FDA for the current standard of care therapy. Additionally, the median duration of response is 15.5 months for pelareorep and atezolizumab compared to 9.5 months ( link to the PR ). Planned Registration Strategy and Accelerated Approval Pathway If the objective response rate and duration of response observed in GOBLET Cohort 4 are reproduced in the planned registration study, Oncolytics believes the resulting dataset would be sufficient to support accelerated approval in this indication, consistent with regulatory precedent in rare cancers with no available therapies. After initial encouraging feedback from KOLS and the FDA, Oncolytics is planning to have a Type C meeting with the FDA in Q1 2026 to discuss and receive guidance on this development plan. References Marabelle et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022 May;7(5):446-454. doi: 10.1016/S2468-1253(21)00382-4. Benson et al. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jun;21(6):653-677. doi: 10.6004/jnccn.2023.0030. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, of which both development programs have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.ir.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @ oncolytics . Forward-looking statements This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; expectations regarding the Company’s proposed design of potential registration studies, including plans to advance pelareorep plus atezolizumab into a registration-directed clinical study in second-line and later SCAC and potential meetings with the FDA; expectations relating to outcomes of ongoing and future studies, in addition to anticipated accelerated FDA approvals; the Company’s goals, strategies and objectives; and its belief in the clinical promise of pelareorep in metastatic anal and other gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Owen Blaschak LifeSci Communications [email protected] View All Press Releases 4350 Executive Drive Suite 325 San Diego, CA 92121 [email protected] Company Our Mission Leadership Board of Directors Careers Contact Science Our Science Pipeline Resources Investors Overview News Events Stock Information Filings Corporate Governance FAQs Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent Copyright © 2026 Oncolytics Biotech Inc. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/lsc-wp-theme-main/*","/wp-content/themes/astra/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} <div class="wcc-consent-container wcc-hide" role="complementary"> <div class="wcc-consent-bar" data-tag="notice" style="background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-notice"> <p id="wcc-title" class="wcc-title" data-tag="title" role="heading" aria-level="1" aria-labelledby="wcc-title" style="color:#212121"></p><div class="wcc-notice-group"> <div id="wcc-notice-des" class="wcc-notice-des" data-tag="description" aria-describedby="wcc-notice-des" style="color:#212121"> <p>We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.</p> </div><div class="wcc-notice-btn-wrapper" data-tag="notice-buttons"> <button class="wcc-btn wcc-btn-customize" aria-label="Customize" data-tag="settings-button" style="color:#001958;background-color:transparent">Customize</button> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Reject All</button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Accept All</button> </div></div></div></div></div><div class="wcc-modal" role="dialog" aria-label="Privacy Overview"> <div class="wcc-preference-center" data-tag="detail" style="color:#212121;background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-preference-header"> <span id="wcc-preference-title" class="wcc-preference-title" data-tag="detail-title" role="heading" aria-level="1" aria-labelledby="wcc-preference-title" style="color:#212121">Privacy Overview</span> <button class="wcc-btn-close" aria-label="Close cookie preference modal" data-tag="detail-close"> <img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/close.svg" alt="Close"> </button> </div><div class="wcc-preference-body-wrapper"> <div class="wcc-preference-content-wrapper" data-tag="detail-description" style="color:#212121"> <p>This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.</p> </div> <div class="wcc-google-privacy-policy" data-tag="google-privacy-policy"> </div><div class="wcc-accordion-wrapper" data-tag="detail-categories"> <div class="wcc-accordion" id="wccDetailCategorynecessary" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Necessary" data-tag="detail-category-title" style="color:#212121">Necessary</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchnecessary"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>wt_consent</div></li><li><div>Duration</div><div>1 year</div></li><li><div>Description</div><div>Used for remembering users’ consent preferences to be respected on subsequent site visits. It does not collect or store personal information about visitors to the site.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_cfuvid</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>Cloudflare sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::a</div></li><li><div>Duration</div><div>never</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::c</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>__cf_bm</div></li><li><div>Duration</div><div>1 hour</div></li><li><div>Description</div><div>This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryanalytics" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Analytics" data-tag="detail-category-title" style="color:#212121">Analytics</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchanalytics"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gid</div></li><li><div>Duration</div><div>1 day</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store information on how visitors use a website while also creating an analytics report of the website's performance. Some of the collected data includes the number of visitors, their source, and the pages they visit anonymously.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gat_gtag_UA_*</div></li><li><div>Duration</div><div>1 minute</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store a unique user ID.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga_*</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store and count page views.</div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryperformance" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Performance" data-tag="detail-category-title" style="color:#212121">Performance</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchperformance"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>INGRESSCOOKIE</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is used for load balancing and session stickiness. This technical session identifier is required for some website features. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryadvertisement" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Advertisement" data-tag="detail-category-title" style="color:#212121">Advertisement</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchadvertisement"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>c</div></li><li><div>Duration</div><div>6 months 2 days</div></li><li><div>Description</div><div>Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.</div></li></ul></div> </div> </div> </div></div><div class="wcc-footer-wrapper"> <span class="wcc-footer-shadow"></span> <div class="wcc-prefrence-btn-wrapper" data-tag="detail-buttons"> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="detail-reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Reject All </button> <button class="wcc-btn wcc-btn-preferences" aria-label="Save My Preferences" data-tag="detail-save-button" style="color:#FFFFFF;background-color:#E8614D;border-color:#E8614D"> Save My Preferences </button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="detail-accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Accept All </button> </div><div style="padding: 8px 24px;font-size: 12px;font-weight: 400;line-height: 20px;text-align: right;border-radius: 0 0 6px 6px;direction: ltr;justify-content: flex-end;align-items: center;background-color:#EDEDED;color:#293C5B" data-tag="detail-powered-by"> Powered by <a target="_blank" rel="noopener" href="https://www.webtoffee.com/product/gdpr-cookie-consent" style="margin-left: 5px;line-height: 0"><img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/webtoffee.svg" alt="Webtoffee logo" style="width: 78px;height: 13px;margin: 0"></a> </div></div></div></div><div class="wcc-overlay wcc-hide"></div> Secret Link ( () => { const lazyloadRunObserver = () => { const lazyloadBackgrounds = document.querySelectorAll( `.e-con.e-parent:not(.e-lazyloaded)` ); const lazyloadBackgroundObserver = new IntersectionObserver( ( entries ) => { entries.forEach( ( entry ) => { if ( entry.isIntersecting ) { let lazyloadBackground = entry.target; if( lazyloadBackground ) { lazyloadBackground.classList.add( 'e-lazyloaded' ); } lazyloadBackgroundObserver.unobserve( entry.target ); } }); }, { rootMargin: '200px 0px 200px 0px' } ); lazyloadBackgrounds.forEach( ( lazyloadBackground ) => { lazyloadBackgroundObserver.observe( lazyloadBackground ); } ); }; const events = [ 'DOMContentLoaded', 'elementor/lazyload/observe', ]; events.forEach( ( event ) => { document.addEventListener( event, lazyloadRunObserver ); } ); } )(); var astra = {"break_point":"1024","isRtl":"","is_scroll_to_id":"","is_scroll_to_top":"","is_header_footer_builder_active":"1","responsive_cart_click":"flyout","is_dark_palette":""}; //# sourceURL=astra-theme-js-js-extra jQuery.uiBackCompat = true; //# sourceURL=jquery-ui-core-js-before jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":1,"isRTL":false});}); //# sourceURL=jquery-ui-datepicker-js-after var astraAddon = {"is_elementor_active":"1","sticky_active":"1","svgIconClose":"\u003Cspan class=\"ast-icon icon-close\"\u003E\u003Csvg viewbox=\"0 0 512 512\" aria-hidden=\"true\" role=\"img\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" width=\"18px\" height=\"18px\"\u003E\n \u003Cpath d=\"M71.029 71.029c9.373-9.372 24.569-9.372 33.942 0L256 222.059l151.029-151.03c9.373-9.372 24.569-9.372 33.942 0 9.372 9.373 9.372 24.569 0 33.942L289.941 256l151.03 151.029c9.372 9.373 9.372 24.569 0 33.942-9.373 9.372-24.569 9.372-33.942 0L256 289.941l-151.029 151.03c-9.373 9.372-24.569 9.372-33.942 0-9.372-9.373-9.372-24.569 0-33.942L222.059 256 71.029 104.971c-9.372-9.373-9.372-24.569 0-33.942z\" /\u003E\n \u003C/svg\u003E\u003C/span\u003E","hf_account_show_menu_on":"hover","hf_account_action_type":"link","hf_account_logout_action":"link","header_main_stick":"1","header_above_stick":"0","header_below_stick":"0","stick_header_meta":"","header_main_stick_meta":"","header_above_stick_meta":"","header_below_stick_meta":"","sticky_header_on_devices":"desktop","sticky_header_style":"none","sticky_hide_on_scroll":"1","break_point":"1024","tablet_break_point":"1024","mobile_break_point":"767","header_main_shrink":"","header_animation_effect":"none","header_logo_width":"","responsive_header_logo_width":{"desktop":180,"tablet":"","mobile":"","desktop-svg-height":42},"stick_origin_position":"","site_layout":"","site_content_width":"1680","site_layout_padded_width":"1200","site_layout_box_width":"1200","header_builder_active":"1","component_limit":"10","is_header_builder_active":"1"}; //# sourceURL=astra-addon-js-js-extra var elementorFrontendConfig = {"environmentMode":{"edit":false,"wpPreview":false,"isScriptDebug":false},"i18n":{"shareOnFacebook":"Share on Facebook","shareOnX":"Share on X","pinIt":"Pin it","download":"Download","downloadImage":"Download image","fullscreen":"Fullscreen","zoom":"Zoom","share":"Share","playVideo":"Play Video","previous":"Previous","next":"Next","close":"Close","a11yCarouselPrevSlideMessage":"Previous slide","a11yCarouselNextSlideMessage":"Next slide","a11yCarouselFirstSlideMessage":"This is the first slide","a11yCarouselLastSlideMessage":"This is the last slide","a11yCarouselPaginationBulletMessage":"Go to slide"},"is_rtl":false,"breakpoints":{"xs":0,"sm":480,"md":521,"lg":1025,"xl":1440,"xxl":1600},"responsive":{"breakpoints":{"mobile":{"label":"Mobile Portrait","value":520,"default_value":767,"direction":"max","is_enabled":true},"mobile_extra":{"label":"Mobile Landscape","value":880,"default_value":880,"direction":"max","is_enabled":false},"tablet":{"label":"Tablet Portrait","value":1024,"default_value":1024,"direction":"max","is_enabled":true},"tablet_extra":{"label":"Tablet Landscape","value":1200,"default_value":1200,"direction":"max","is_enabled":true},"laptop":{"label":"Laptop","value":1366,"default_value":1366,"direction":"max","is_enabled":true},"widescreen":{"label":"Widescreen","value":1901,"default_value":2400,"direction":"min","is_enabled":true}},"hasCustomBreakpoints":true},"version":"4.3.2","is_static":false,"experimentalFeatures":{"additional_custom_breakpoints":true,"container":true,"nested-elements":true,"import-export-customization":true,"e_pro_atomic_form":true,"e_pro_collection_loop":true},"urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor\/assets\/","ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","uploadUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/uploads"},"nonces":{"floatingButtonsClickTracking":"0d90cb1536","atomicFormsSendForm":"3c7937a4a7"},"swiperClass":"swiper","settings":{"page":[],"editorPreferences":[]},"kit":{"active_breakpoints":["viewport_mobile","viewport_tablet","viewport_tablet_extra","viewport_laptop","viewport_widescreen"],"viewport_widescreen":1901,"viewport_mobile":520,"global_image_lightbox":"yes","lightbox_enable_counter":"yes","lightbox_enable_fullscreen":"yes","lightbox_enable_zoom":"yes","lightbox_enable_share":"yes","lightbox_title_src":"title","lightbox_description_src":"description"},"post":{"id":7265,"title":"Oncolytics%20Biotech%C2%AE%20Announces%20Updated%20Clinical%20Data%20from%20GOBLET%20Cohort%204%20Demonstrating%20Activity%20of%20Pelareorep%20Plus%20Atezolizumab%20in%20Third-Line%20Anal%20Cancer%20%7C%20Oncolytics%20Biotech%20Inc.","excerpt":"","featuredImage":false}}; //# sourceURL=elementor-frontend-js-before wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var ElementorProFrontendConfig = {"ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","nonce":"3b9774f4ab","urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/assets\/","rest":"https:\/\/ir.oncolyticsbiotech.com\/wp-json\/"},"settings":{"lazy_load_background_images":true},"popup":{"hasPopUps":false},"shareButtonsNetworks":{"facebook":{"title":"Facebook","has_counter":true},"twitter":{"title":"Twitter"},"linkedin":{"title":"LinkedIn","has_counter":true},"pinterest":{"title":"Pinterest","has_counter":true},"reddit":{"title":"Reddit","has_counter":true},"vk":{"title":"VK","has_counter":true},"odnoklassniki":{"title":"OK","has_counter":true},"tumblr":{"title":"Tumblr"},"digg":{"title":"Digg"},"skype":{"title":"Skype"},"stumbleupon":{"title":"StumbleUpon","has_counter":true},"mix":{"title":"Mix"},"telegram":{"title":"Telegram"},"pocket":{"title":"Pocket","has_counter":true},"xing":{"title":"XING","has_counter":true},"whatsapp":{"title":"WhatsApp"},"email":{"title":"Email"},"print":{"title":"Print"},"x-twitter":{"title":"X"},"threads":{"title":"Threads"}},"facebook_sdk":{"lang":"en_US","app_id":""},"lottie":{"defaultAnimationUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/modules\/lottie\/assets\/animations\/default.json"}}; //# sourceURL=elementor-pro-frontend-js-before /(trident|msie)/i.test(navigator.userAgent)&&document.getElementById&&window.addEventListener&&window.addEventListener("hashchange",function(){var t,e=location.hash.substring(1);/^[A-z0-9_-]+$/.test(e)&&(t=document.getElementById(e))&&(/^(?:a|select|input|button|textarea)$/i.test(t.tagName)||(t.tabIndex=-1),t.focus())},!1);

The release as fetched from its publisher. oncolyticsbiotech.com ↗